The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Jan. 22, 2018
Applicant:

Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, DE;

Inventors:

Matthias Eckhardt, Biberach an der Riss, DE;

Holger Wagner, Mettenberg, DE;

Stefan Peters, Biberach an der Riss, DE;

Assignee:

Boehringer Ingelheim International GmbH, Ingelheim am Rhein, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 241/20 (2006.01); A61K 31/4965 (2006.01); A61K 45/06 (2006.01); A61K 31/497 (2006.01); A61P 9/00 (2006.01); A61P 3/10 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); C07D 403/12 (2006.01); C07D 401/10 (2006.01); C07D 403/10 (2006.01); C07D 405/10 (2006.01); C07D 409/10 (2006.01); C07D 413/10 (2006.01); C07D 417/10 (2006.01);
U.S. Cl.
CPC ...
C07D 241/20 (2013.01); A61K 31/497 (2013.01); A61K 31/4965 (2013.01); A61K 45/06 (2013.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A61P 9/00 (2018.01); C07D 401/10 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 405/10 (2013.01); C07D 409/10 (2013.01); C07D 413/10 (2013.01); C07D 417/10 (2013.01);
Abstract

The present invention relates to compounds of formula I, wherein the groups R, R, R, R, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.


Find Patent Forward Citations

Loading…